Blueprint Medicines (BPMC) Competitors $96.48 +1.09 (+1.14%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BPMC vs. TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, CTLT, and PCVXShould you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Blueprint Medicines vs. Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Blueprint Medicines (NASDAQ:BPMC) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability. Which has more volatility & risk, BPMC or TEVA? Blueprint Medicines has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Is BPMC or TEVA more profitable? Teva Pharmaceutical Industries has a net margin of -5.73% compared to Blueprint Medicines' net margin of -29.48%. Teva Pharmaceutical Industries' return on equity of 42.92% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-29.48% -112.30% -26.87% Teva Pharmaceutical Industries -5.73%42.92%7.25% Does the MarketBeat Community favor BPMC or TEVA? Teva Pharmaceutical Industries received 789 more outperform votes than Blueprint Medicines when rated by MarketBeat users. However, 68.11% of users gave Blueprint Medicines an outperform vote while only 67.77% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformBlueprint MedicinesOutperform Votes53668.11% Underperform Votes25131.89% Teva Pharmaceutical IndustriesOutperform Votes132567.77% Underperform Votes63032.23% Do analysts rate BPMC or TEVA? Blueprint Medicines currently has a consensus target price of $122.11, indicating a potential upside of 26.56%. Teva Pharmaceutical Industries has a consensus target price of $20.50, indicating a potential downside of 1.82%. Given Blueprint Medicines' higher possible upside, research analysts plainly believe Blueprint Medicines is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 2.71Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has preferable earnings & valuation, BPMC or TEVA? Blueprint Medicines has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Blueprint Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$434.42M14.11-$506.98M-$2.11-45.73Teva Pharmaceutical Industries$16.77B1.41-$559M-$0.85-24.56 Does the media favor BPMC or TEVA? In the previous week, Teva Pharmaceutical Industries had 7 more articles in the media than Blueprint Medicines. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 11 mentions for Blueprint Medicines. Teva Pharmaceutical Industries' average media sentiment score of 0.76 beat Blueprint Medicines' score of 0.74 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in BPMC or TEVA? 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryTeva Pharmaceutical Industries beats Blueprint Medicines on 12 of the 19 factors compared between the two stocks. Ad Diversified Trading InstituteGenesis leading the smart algo revolution?I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before… Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from. Here’s why: It does all the heavy lifting for you… automatically. Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart!You’ll want to see what I’ve put on this page right here Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPMC vs. The Competition Export to ExcelMetricBlueprint MedicinesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.13B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-45.7210.75135.1817.53Price / Sales14.11287.861,235.42140.39Price / CashN/A56.6540.6537.95Price / Book44.875.394.884.92Net Income-$506.98M$152.04M$118.97M$225.78M7 Day Performance2.13%-4.32%16.19%-1.58%1 Month Performance6.99%2.80%16.02%6.67%1 Year Performance10.12%17.30%34.95%22.48% Blueprint Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPMCBlueprint Medicines2.9172 of 5 stars$96.48+1.1%$122.11+26.6%+9.7%$6.13B$434.42M-45.72640Insider TradeShort Interest ↑TEVATeva Pharmaceutical Industries2.0247 of 5 stars$16.65+0.9%$19.67+18.1%+109.2%$18.86B$16.77B-19.7937,851Options VolumeNews CoverageGap UpBGNEBeiGene2.6509 of 5 stars$176.80-1.4%$253.69+43.5%-2.2%$17.23B$2.46B-21.7710,600MRNAModerna4.4064 of 5 stars$41.65-0.4%$79.50+90.9%-52.6%$16.03B$5.06B-7.195,600VTRSViatris1.4196 of 5 stars$12.69+0.5%$13.67+7.7%+22.6%$15.15B$15.05B-17.0738,000SMMTSummit Therapeutics3.4066 of 5 stars$18.81+5.5%$33.33+77.2%+625.4%$13.87B$700,000.00-63.68105GMABGenmab A/S4.2563 of 5 stars$20.14-0.1%$45.20+124.4%-35.1%$13.33B$19.84B19.582,204Short Interest ↓High Trading VolumeRDYDr. Reddy's Laboratories2.1274 of 5 stars$14.76+2.1%$17.00+15.2%+8.6%$12.32B$299.87B22.9527,048SRPTSarepta Therapeutics4.9058 of 5 stars$126.12+1.9%$178.71+41.7%+35.2%$12.05B$1.64B98.971,314Insider TradePositive NewsCTLTCatalent2.7772 of 5 stars$63.48+0.7%$63.40-0.1%+53.0%$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.8076 of 5 stars$90.42+3.1%$147.50+63.1%+48.4%$11.27BN/A-19.07160 Related Companies and Tools Related Companies TEVA Competitors BGNE Competitors MRNA Competitors VTRS Competitors SMMT Competitors GMAB Competitors RDY Competitors SRPT Competitors CTLT Competitors PCVX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BPMC) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPMC Stock Alerts